Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive ...

Study published in the Journal of Clinical PsychopharmacologySALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad ...

Gov. Brian Kemp signed into law an overhaul of the state's litigation system aimed at bringing down insurance costs.

In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

NASDAQ MYGN opened at $7.95 on Friday. Myriad Genetics, Inc. has a 52 week low of $7.35 and a 52 week high of $29.30. The firm has a market capitalization of $725.91 million, a price-to-earnings ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to Neutral. Analyst Price Forecast Suggests 107.09% Upside As of April 1 ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with the ...

SALT LAKE CITY, April 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today that in connection with ...